ver-AP-a-mil 
Unlabeled Use:
Absorption: 90% absorbed after oral administration, but much is rapidly metabolized, resulting in bioavailability of 20–25%.
Distribution: Small amounts enter breast milk.
Protein Binding: 90%.
Metabolism/Excretion: Mostly metabolized by the liver (primarily by CYP3A4).
Half-life: 4.5–12 hr.
Contraindicated in:
Use Cautiously in:
CV: ARRHYTHMIAS, HF, bradycardia, chest pain, hypotension, palpitations, peripheral edema, syncope, tachycardia.
Derm: STEVENS-JOHNSON SYNDROME (SJS), dermatitis, erythema multiforme, flushing, photosensitivity, pruritus/urticaria, rash, sweating.
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.
Endo: gynecomastia, hyperglycemia.
GI: ↑liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting.
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.
Hemat: anemia, leukopenia, thrombocytopenia.
Metab: weight gain.
MS: joint stiffness, muscle cramps.
Neuro: dysgeusia, paresthesia, tremor , abnormal dreams, anxiety, confusion, dizziness/lightheadedness, drowsiness, extrapyramidal reactions, headache, jitteriness, nervousness, psychiatric disturbances, weakness.
Resp: cough, dyspnea.
Misc: gingival hyperplasia.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
IV Administration:
Calan, Calan SR, Verelan, Verelan PM
Therapeutic Classification: antianginals, antiarrhythmics (class IV), antihypertensives, vascular headache suppressants
Pharmacologic Classification: calcium channel blockers
(Generic available)
(cardiovascular effects)
†Single dose; effects from multiple doses may not be evident for 24–48 hr.
†Antiarrhythmic effects; hemodynamic effects begin 3–5 min after injection and persist for 10–20 min.
NDC Code*